Danone reports Q3 revenue EUR 6.876B vs. EUR 6.826B last year

In Q3 2025, consolidated sales stood at EUR 6.876B, up +4.8% on a like-for-like basis, led by an increase of +3.2% from volume/mix and +1.6% from price. On a reported basis, sales increased by +0.7%, including a positive impact from scope resulting predominantly from the acquisition of Kate Farms in the US. Reported sales were negatively impacted by forex, reflecting the depreciation of several currencies against the euro, notably the US Dollar, the Chinese Renminbi, the Indonesian Rupiah, the Argentine Peso and the Turkish Lira. In addition, hyperinflation contributed positively to reported sales. Antoine de Saint-Affrique, CEO said, “We continued to deliver consistent, quality growth this quarter, with volume/mix being the primary growth driver across our categories, confirming the strength and the relevance of our health-focused portfolio. We are particularly pleased with the step-by-step improvement in Europe, where volume/mix has now been positive for eight consecutive quarters, while CNAO delivered another outstanding performance across all categories. At the same time, we recognize that our transformation journey is not over and that some areas require further progress. We stay focused on fully leveraging our science-based and value-added portfolio, while continuing to execute with discipline and agility. In what remains a volatile and uncertain environment, we are confident in our direction, deploying chapter two of our Renew Danone (DANOY) strategy to deliver on our mid-term ambition.”